Universitätsklinikum Würzburg

Complete revascularization versus culprit-lesion only PCI in patients with NSTEMI and multivessel disease – Design and rationale of the randomized COMPLETE-NSTEMI trial (2025) Feistritzer HJ, Jobs A, Zeymer U, Schneider S, Lauten P, Ferenc M, Weferling M, et al. Journal article Comorbidities and Their Influence on Outcomes and Infectious Complications in Autoimmune Encephalitis A Multicenter Cohort Study (2025) Bohn A, Angstwurm K, Bien CG, Doppler K, Ehmke L, Havla J, Hoffmann F, et al. Journal article Modulatory effect of various essential oils on different GABAA receptor subtypes present in the central nervous system (2025) Böhm C, Wiessler AL, Janzen D, Nausester J, Slavik B, Loos H, Villmann C, Büttner A Journal article 3D anthropometry of the nasolabial region in children aged 3 to 9 months as reference database for clinical assessment (2025) Olmos M, Backhaus J, Weber M, Matta R, Vogl C, Schulz K, Beyer S, et al. Journal article Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma. (2025) DeTemple VK, Kaatz M, Stockfleth E, Scheel C, Angela Y, Gutzmer R, Leiter U, et al. Journal article One CHiP to rule them all? Mechanistic insight into carfilzomib-induced lung injury with neutrophil extracellular trap formation following cellular immunotherapy (2025) Scholz JK, Stabel L, Schwingen NR, Knopf J, Flatt AS, Bäuerle T, Krause S, et al. Journal article, Medical case study Digital empowerment on hold: DiGA adoption gaps−a German national cross-sectional patient survey study (2025) Kremer P, Fink D, Morf H, Labinsky H, Gente K, Aries P, Krusche M, et al. Journal article Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study (2025) Decker T, Brucker C, Engel A, Fasching P, Göhler T, Jackisch C, Janssen J, et al. Journal article Organ preservation after total neoadjuvant therapy for locally advanced rectal cancer (CAO/ARO/AIO-16): an open-label, multicentre, single-arm, phase 2 trial (2025) Gani C, Fokas E, Polat B, Ott O, Diefenhardt M, Königsrainer A, Böke S, et al. Journal article MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade glioma (2025) Friker LL, Perwein T, Waha A, Dörner E, Klein R, Blattner-Johnson M, Layer JP, et al. Journal article